Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity

Molecular Pharmacology

Volumn 75, Issue 3, 2009, Pages 658-666

  Ciccimaro, Eugene ^a   Hanks, Steven K ^b   Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PERVANADATE; PROTEIN TYROSINE KINASE; TYROSINE; BIOLOGICAL MARKER; PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL LINE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MICE; PHOSPHORYLATION; PROTEASE INHIBITORS; SRC-FAMILY KINASES;

EID: 62149101618     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.052464     Document Type: Article

References (35)

1. Basson MD (2008) An intracellular signal pathway that regulates cancer cell adhesion ni response to extracellular forces. Cancer Res 68:2-4.
2. Beis I and Newsholme EA (1975) The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem J 152:23-32.
3. Brábek J, Constancio SS, Shin NY, Pozzi A, Weaver AM, and Hanks SK (2004) CAS promotes invasiveness of Src-transformed cells. Oncogene 23:7406-7415.
4. Calalb MB, Polte TR, and Hanks SK (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src-family kinases. Mol Cell Biol 15:954-963.
5. Ciccimaro E, Hevko J, and Blair IA (2006) Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry. Rapid Commun Mass Spectrom 20:3681-3692.
6. Cooper JA, Gould KL, Cartwright CA, and Hunter T (1986) Tyr527 is phosphorylated hi Pp60c-Src: implications for regulation. Science 231:1431-1434.
7. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, and Connelly PA (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and Fyn T-dependent T cell activation. J Biol Chem 271:695-701.
8. Hanke S, Besir H, Oesterhelt D, and Mann M (2008) Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Pro-teome Res 7:1118-1130.
9. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, et al. (2006) N-(5-cMoro-l,3- benzodioxol-4-Yl)-7-[2-(4-methylpiperazin-l-Yl)ethoxy]-5- (tetraliydro-2H-pyran-4-yloxy)quhiazolin-4-amine, a novel, highly selective, orally available, dual-specific C-Src/Abl kinase inhibitor. J Med Chem 49:6465-6488.
10. Hiscox S and Nicholson RI (2008) Src inhibitors hi breast cancer therapy. Expert Opin Ther Targets 12:757-767.
11. Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW, and Bruns CJ (2007) Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10:167-182.
12. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, and Rabbani SA (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer hivasion, growth, and metastasis in vitro and in vivo. Cancer Res 67:1580-1588.
13. Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvm P, Womack C, Clack G, et al. (2008) Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Res Treat doi:10.1007/sl0549-008-9997-l.
14. Kansra S, Stoll SW, Johnson JL, and Elder JT (2005) Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratin-ocytes. Mol Pharmacol 67:1145-1157.
15. Luo W, Slebos RJ, Hill S, Li M, Brábek J, Amanchy R, Chaerkady R, Pandey A, Ham AJ, and Hanks SK (2008) Global impact of oncogenic Src on a phosphotyrosine proteonie. J Proteome Res 7:3447-3460.
16. Maa MC and Leu TH (1998) Vanadate-dependent FAK activation is accomplished by the sustained FAK Tyr-576/577 phosphorylation. Biochem Biophys Res Commun251:344-349.
17. Meyn MA 3rd and Smithgall TE (2008) Small molecule inhibitors of Lck: the search for specificity within a kinase family. Mini Rev Med Chem 8:628-637.
18. Mishra R, Wang Y, and Shnonson MS (2005) Cell cycle signaling by endothelin-1 requires Src nonreceptor protein tyrosine kinase. Mol Pharmacol 67:2049-2056.
19. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, and Susa M (1999) A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24:437-449.
20. Okada M and Nakagawa H (1989) A protein tyrosine kinase involved in regulation of Pp60c-Src function. J Biol Chem 264:20886-20893.
21. Owen JD, Ruest PJ, Fry DW, and Hanks SK (1999) Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and hihibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 19:4806-4818.
22. Ozawa Y, Williams AH, Estes ML, Matsushita N. Boschelh F, Jove R, and List AF (2008) Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 32:893-903.
23. Park SI, Zhang J. Phillips KA, Araujo JC. Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, and Gallick GE (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.Cancer Res 68:3323-3333.
24. Pié PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, Lambert-Van Der Brempt C, and Costello G (2004) Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.J Med Chem 47:871-887.
25. Rucci N, Susa M, and Teti A (2008) Inhibition of protein kinase C-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 8:342-349.
26. Ruest PJ, Roy S, Shi E, Mernaugh RL, and Hanks SK (2000) Phosphospecific antibodies reveal focal adhesion kinase activation loop phosphorylation in nascent and mature focal adhesions and requirement for the autophosphorylation site. Cell Growth Differ 11:41-48.
27. Sawyer TK (2004) Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 13:1-19.
28. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, and Brunton VG (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5:3014-3022.
29. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ,and Jove R (2007) Dasatinib inhibits migration, and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800-2808.
30. Summy JM and Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337-358.
31. Summy JM, Trevino JG, Baker CH, and Gallick GE (2005) C-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and P38 MAPK. Pancreas 31:263-274.
32. Thomas SM and Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609.
33. Torizawa T, Shimizu M, Taoka M, Miyano H, and Kainosho M (2004) Efficient production of isotopically labeled proteins by cell-free synthesis: a practical protocol. J Biomol NMR 30:311-325.
34. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, and Jove R (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7:1185-1194.
35. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470-480.